0001209191-23-025397.txt : 20230424 0001209191-23-025397.hdr.sgml : 20230424 20230424163314 ACCESSION NUMBER: 0001209191-23-025397 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230421 FILED AS OF DATE: 20230424 DATE AS OF CHANGE: 20230424 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Davis Stephanie A CENTRAL INDEX KEY: 0001771886 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38112 FILM NUMBER: 23840518 MAIL ADDRESS: STREET 1: C/O ATHENEX, INC. STREET 2: 1001 MAIN STREET, SUITE 600 CITY: BUFFALO STATE: NY ZIP: 14203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Athenex, Inc. CENTRAL INDEX KEY: 0001300699 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 431985966 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1001 MAIN STREET STREET 2: SUITE 600 CITY: BUFFALO STATE: NY ZIP: 14203 BUSINESS PHONE: 716-898-8625 MAIL ADDRESS: STREET 1: 1001 MAIN STREET STREET 2: SUITE 600 CITY: BUFFALO STATE: NY ZIP: 14203 FORMER COMPANY: FORMER CONFORMED NAME: Kinex Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20131223 FORMER COMPANY: FORMER CONFORMED NAME: Kinex Pharmaceuticals LLC DATE OF NAME CHANGE: 20040817 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-04-21 0 0001300699 Athenex, Inc. ATNX 0001771886 Davis Stephanie A C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600 BUFFALO NY 14203 1 0 0 0 0 Common Stock 2023-04-21 4 A 0 3642 1.305 A 8015 D Stock Option (Right to Buy) 241.20 2023-04-01 2029-04-01 Common Stock 500 500 D Stock Option (Right to Buy) 229.80 2023-04-03 2029-04-03 Common Stock 375 375 D Stock Option (Right to Buy) 249.00 2030-06-05 Common Stock 875 875 D Stock Option (Right to Buy) 76.00 2022-08-03 2031-08-03 Common Stock 438 438 D Stock Option (Right to Buy) 9.14 2032-06-28 Common Stock 875 875 D Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase. As of February 15, 2023, the issuer effected a reverse stock split of its common stock at a ratio of 1-for-20, resulting in every 20 shares owned by the reporting person to be combined into one share of common stock. This option was adjusted to reflect the reverse stock split that occurred on February 15, 2023. This option vests in four equal annual installments beginning on June 5, 2021. This option vests on June 28, 2023. /s/Staci Holquist, Attorney-in-Fact 2023-04-24